Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

News Daily News

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

July 02, 2024

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

July 11, 2023

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

News Daily News

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

February 01, 2021

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.